Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Combinations in Early Relapsing or Refractory Follicular Lymphoma
NCT03269669Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of umbralisib and lenalidomide in follicular lymphoma (FL) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Complete Response. Started Jan 2018; status: active, not recruiting.
02
Drugs
umbralisiblenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03269669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03269669.